Source:http://linkedlifedata.com/resource/pubmed/id/10071461
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1999-4-22
|
| pubmed:abstractText |
We have established a pre-B acute lymphoblastic leukemia (ALL) cell line, NAGL-1, from the bone marrow of a patient diagnosed with pre-B ALL. The patient has been disease-free for the 4 years since allogeneic bone marrow transplantation from her HLA-genotypically identical sister. NAGL-1 showed a pre-B cell phenotype (CD19+, CD10+, c mu+, s mu-) mostly identical to freshly isolated leukemic cells from the patient. This cell line strongly expressed HLA class I and HLA-DR molecules, as well as the costimulatory molecules CD54, CD40, and CD86. Cytotoxic T-lymphocyte (CTL) lines were generated by stimulating the donor-derived peripheral blood mononuclear cells with either irradiated leukemic cells or NAGL-1. Both CTL lines showed specific lysis against NAGL-1 in 51Cr release assays. Lytic activity was partially inhibited by anti-CD8 and anti-HLA class I monoclonal antibodies. Treatment of NAGL-1 with TNF-alpha increased its susceptibility to the CTL line. One CD8+ T cell clone derived from the CTL line killed both the patient phytohemagglutinin (PHA) blasts and NAGL-1 but not the donor PHA blasts, suggesting that the clone recognized the patient-specific minor antigen presented on both PHA blasts and NAGL-1. Utilization of leukemic cell lines could be a useful model for the development of CTL lines and clones for immunological study and potential immunotherapy.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0925-5710
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
69
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
112-8
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10071461-Adolescent,
pubmed-meshheading:10071461-Antigens, CD,
pubmed-meshheading:10071461-Antigens, Neoplasm,
pubmed-meshheading:10071461-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:10071461-Bone Marrow Transplantation,
pubmed-meshheading:10071461-Clone Cells,
pubmed-meshheading:10071461-Combined Modality Therapy,
pubmed-meshheading:10071461-Cytotoxicity, Immunologic,
pubmed-meshheading:10071461-Disease-Free Survival,
pubmed-meshheading:10071461-Female,
pubmed-meshheading:10071461-Graft vs Tumor Effect,
pubmed-meshheading:10071461-HLA-DR Antigens,
pubmed-meshheading:10071461-Humans,
pubmed-meshheading:10071461-Immunophenotyping,
pubmed-meshheading:10071461-Lymphocyte Culture Test, Mixed,
pubmed-meshheading:10071461-Precursor B-Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:10071461-Precursor Cell Lymphoblastic Leukemia-Lymphoma,
pubmed-meshheading:10071461-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:10071461-Transplantation, Homologous,
pubmed-meshheading:10071461-Tumor Cells, Cultured
|
| pubmed:year |
1999
|
| pubmed:articleTitle |
Immune response of post-transplant peripheral lymphocytes against the patient pre-B cell line, NAGL-1.
|
| pubmed:affiliation |
First Department of Internal Medicine, Nagoya University School of Medicine, Japan.
|
| pubmed:publicationType |
Journal Article,
Case Reports,
Research Support, Non-U.S. Gov't
|